Glenmark Pharma Recalls 15 Lakh Bottles of ADHD Medication in the US

is recalling 15 lakh bottles of ADHD medication in the United States due to the presence of N-Nitroso Atomoxetine impurity exceeding the FDA’s recommended limit. This voluntary recall highlights the stringent quality and safety standards that pharmaceutical companies must adhere to in regulated markets like the US. While such recalls are not uncommon, they can have financial and reputational impacts on pharmaceutical firms. The recall reinforces the importance of stringent quality control measures at every stage of drug manufacturing, from raw material sourcing to final product distribution. Regulatory scrutiny in global markets remains high, and ensuring compliance with evolving safety norms is crucial for sustaining long-term growth. Learning Comment: In the pharmaceutical industry, maintaining regulatory compliance is critical for market access and brand trust. Companies must invest in robust quality control mechanisms, advanced testing protocols, and proactive risk mitigation strategies to minimize the likelihood of product recalls and maintain their standing in highly regulated markets. Source: NDTV Profit No Recommendations